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Type 1 diabetes is caused by specific destruction of
pancreatic  cells which, in turn, is caused by activation
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of islet-antigen-specific T cells. The NOD mouse is2INSERM U25 and
widely used as a model of insulin-dependent diabetes3INSERM U345
mellitus (IDDM), as it spontaneously develops a diseaseHoˆpital Necker
very similar to human diabetes (Bach, 1994). Diabetes75015 Paris
onset is preceded by infiltration of pancreatic islets byFrance
macrophages, dendritic cells, and T and B lymphocytes.
Various strategies designed to block the activation and/
or migration of pathogenic anti-islet Th1 cells can pro-Summary
tect against diabetes (Lenschow et al., 1995). The emer-
gence of diabetogenic T cells appears to be associatedTo determine the precise regulatory effect of NKT cells
with defective immunoregulation (Delovitch and Singh,on CD4 T cells involved in autoimmune diabetes, we
1997). Both IDDM patients and NOD mice have reduceddeveloped an in vivo model in which transferred naive
numbers of NKT cells, which are also functionally defi-transgenic T cells are stimulated by their antigen in the
cient (Baxter et al., 1997; Gombert et al., 1996; Wilsonpresence or absence of NKT cells or in the presence of
et al., 1998). NOD mice can be protected against diabe-another conventional transgenic  T cell. The pres-
tes by increasing the number of NKT cells, by cell trans-ence of NKT cells did not block the initial activation
fer, or by transgenesis (Hammond et al., 1998; Lehuen etand expansion of the CD4 T cells but did inhibit their
al., 1998). Conversely, the NKT cell deficiency in CD1/IL-2 and IFN- production and later proliferation, re-
NOD mice exacerbates disease development (Wang etsulting in an anergic phenotype. These CD4 T cells
al., 2001). It has also recently been shown that in vivodid not induce significant insulitis and were unable to
activation of NKT cells by -GalCer treatment protectsdestroy the  cells. Thus, NKT cells prevent  CD4
NOD mice against diabetes (Hong et al., 2001; Sharif etT cell differentiation into effector cells.
al., 2001). All these data support a role for NKT cells in
protection against diabetes, but the underlying mecha-Introduction
nisms remain to be elucidated.
We have previously reported that NOD mice trans-NKT cells, which are nonconventional  T cells, have
genic for the invariant V14-J281 TCR  chain exhibitbeen conserved through mammalian evolution. NKT
elevated numbers of NKT cells and that this increasecells are restricted by a nonpolymorphic MHC class
correlates with the efficiency of protection against dia-I-like molecule named CD1d, which presents self and
betes (Lehuen et al., 1998). Analysis of diabetes-freeforeign glycolipids (Bendelac et al., 1997; Gumperz et
V14-J281 (V14) transgenic NOD mice showed thatal., 2000; Kawano et al., 1997). NKT cells are found in
islets contained decreased IFN- mRNA levels and in-normal numbers in germ-free mice and therefore do not
creased IL-4 mRNA levels. Similarly, the IgG1/IgG2c ra-require stimulation by pathogens or foreign antigens for
tio of autoantibodies against glutamic acid decarboxyl-their expansion. Most NKT cells express an invariant
ase was increased (Laloux et al., 2001). These data
TCR chain composed of V14-J281 segments in mice
suggested that NKT cells prevent the full development
and V24-JQ segments in humans, associated with
of pathogenic anti- cell Th1 responses, although the
TCR  chains using a restricted set of V genes (Lantz precise effect of NKT cells on pathogenic T cells was
and Bendelac, 1994). NKT cells express molecules com- difficult to determine. Previous studies have shown that
mon to the NK cell lineage, such as NK1.1, CD122, and islet-reactive naive T cells are first activated in pancre-
various Ly49 molecules. They also have an activated atic lymph nodes before migrating to the islets (Hoglund
phenotype (CD69CD44high). After triggering of their TCR et al., 1999). Interestingly, NKT cells, which are rare in
by monoclonal antibodies or the specific ligand peripheral lymph nodes (0.03%), are relatively abundant
-galactosyl-ceramide (-GalCer), NKT cells rapidly re- (0.2%) in pancreatic lymph nodes (Laloux et al., 2002).
lease large amounts of cytokines such as IL-4 and IFN- The presence of NKT cells in pancreatic lymph nodes
(Burdin et al., 1999; Carnaud et al., 2001). Several au- and islets suggests that they might interfere with the
thors have reported that NKT cells can provide help development of the autoimmune response in both tis-
during Th1 responses against various pathogens and sues. Several possibilities could account for inhibition
tumors (Cui et al., 1997; Denkers et al., 1996; Pied et of the destructive Th1 anti-islet response. First, NKT
al., 2000). NKT cells can also prevent the development cells could kill activated diabetogenic T cells, as it has
of pathological autoimmune responses leading to disor- been proposed that NKT cells exert cytolytic activity
ders such as type 1 diabetes, experimental autoimmune through Fas- or perforin-dependent mechanisms (Ka-
encephalomyelitis, and graft-versus-host disease (Ham- neko et al., 2000). Second, NKT cells could influence T
cell differentiation, driving effector cells toward a non-
pathogenic Th2 profile (Singh et al., 1999). Third, NKT4Correspondence: lehuen@cochin.inserm.fr
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cells could inhibit the development of an efficient Th1 following transfer of BDC2.5 T cells, either naive or after
in vitro activation and differentiation toward a Th1 cyto-response by interfering with the priming, differentiation,
and/or expansion of  cell-specific Th1 cells. kine production profile. CD4 BDC2.5 T cells were ob-
tained from spleens of 5- to 7-week-old nondiabeticTo study the mechanisms underlying the inhibitory
action of NKT cells on the development of anti- cell BDC2.5 C/ NOD mice. As shown in the middle panel
of Figure 2A, 23% of CD4 splenocytes from theseTh1 responses, we have developed a transfer model
based on the monoclonal population of naive diabeto- mice had an activated phenotype (CD44high CD62L).
To obtain an enriched population of naive CD4 T cells,genic T cells from BDC2.5 transgenic C-deficient mice.
These cells exclusively express the rearranged TCR  splenocytes from BDC2.5 C/ mice were positively
selected on the basis of CD62L expression, yielding a(V1) and  (V4) chain genes from a diabetogenic, 
cell-specific CD4 T cell clone isolated from a diabetic population that was 96% CD44low CD62L (Figure 2A,
left panel). Transfer of 250,000 to 106 CD62L CD4NOD mouse (Katz et al., 1993). These potentially harmful
CD4 T cells were transferred into recipient mice con- BDC2.5 cells into C/ NOD mice or V8 C/ NOD
mice induced diabetes after 10 to 15 days in 80% totaining or not containing NKT cells, allowing us to ana-
lyze the effect of NKT cells on the activation, prolifera- 100% of recipients (Figure 2B, left panel). In striking
contrast, when the same diabetogenic population wastion, differentiation, and migration of anti-islet CD4 T
cells. We found that NKT cells inhibit the expansion and injected into V14 C/ NOD recipients, which contain
large numbers of NKT cells, only 2 of 27 mice developedfull differentiation of anti- cell T lymphocytes, rendering
them unable to destroy pancreatic islets. The T cells diabetes. These experiments show that NKT cells effi-
ciently protect against diabetes onset. Interestingly,appear to be anergic. This is the first major insight into
the mechanism by which NKT cells protect against dia- NKT cells also protected against diabetes induced by
transfer of the entire BDC2.5 cell population, which con-betes.
tained 23% of activated CD4 T cells (Figure 2B, middle
panel). However, NKT cells were not protective whenResults
diabetes was induced by transfer of BDC2.5 T cells that
had first been activated in vitro with concanavalin A inCharacterization of Recipient Mice Containing
the presence of IL-12 and the IL-4-blocking mAb, 11B11or Not Containing NKT Cells
(CD4 Th1 cells in Figure 2B, right panel). This observa-V14 C/ NOD mice express a high frequency of
tion suggests that NKT cells do not act at the levelNK1.1  T cells and most of the NK1.1  T cells
of already differentiated T cells but rather affect thedisplay many characteristics of bona fide NKT cells (acti-
activation and/or differentiation of naive T cells.vation markers, V usage, absence of CD8 coreceptor).
In order to demonstrate that V14-J281 T cells wereTo analyze the precise effect of NKT cells in the protec-
responsible for the protection, C/NOD recipient micetion against diabetes, we developed a transfer model
were reconstituted with CD5 T cells from V14 C/of diabetogenic BDC2.5 T cells into recipient V14 C/
NOD mice. These T cells are NK1.1  T cells or NK1.1NOD mice. Two types of recipient mice that did not
 T cells displaying many characteristics of NKT cells:contain NKT cells were used as controls: either C/
they are all CD44, CD122, biased toward V8 usage,NOD mice or, to rule out a nonspecific effect of  T
do not express CD8 coreceptor, and respond to IL-12lymphocytes, a transgenic line expressing V8-J37, a
(data not shown). Such NK1.1 CD1d-restricted NKTTCR  chain not associated with NKT cells. V8 trans-
cells have been previously described (Benlagha et al.,genic line is also an important control to exclude differ-
2002; Matsuda et al., 2000; Pellicci et al., 2002). Naiveences between lymphopenic and nonlymphopenic re-
BDC2.5 T cells were transferred into C/ NOD recipi-cipients. As shown in Figure 1A, V14 C/ NOD mice
ents previously reconstituted with the T cells from V14and V8 C/ NOD mice were similar in terms of total
C/ NOD mice. These recipients were also protectedcell numbers and percentages of  T cells in lymphoid
against the development of diabetes (Figure 2C). Thisorgans (spleen and pancreatic lymph nodes). Immuno-
experiment further demonstrates that V14-J281 NKTfluorescence staining of pancreatic lymph nodes (Figure
cells are indeed responsible for the protection.1B) showed NK1.1 T cells only in the V14 C/ NOD
recipient. Furthermore, V8 C/ NOD mice did not
harbor NKT cell activity because  T cells from these NKT Cells Inhibit the Development of Severe Insulitis
mice did not respond to stimulation with -GalCer (Fig- Induced by BDC2.5 T Cells
ure 1C). In contrast,  T cells from V14 C/ NOD To determine the degree of pancreatic infiltration by
mice proliferated strongly in the presence of this NKT inflammatory cells in protected V14 C/ mice, pan-
cell-specific stimulus. The  T cells from both TCR creatic sections were examined histologically and
transgenic mice responded equally well to anti-CD3 scored for insulitis (Figure 2D). On day 4 after transfer
stimulation (Figure 1C). Altogether, these results sug- of CD62L CD4 BDC2.5 cells, there was no detectable
gest that V8 C/ NOD mice are a good negative islet infiltration in C/ and V14 C/ recipients and
control for V14 C/ NOD mice in analyzing the effect only very limited peri-insulitis in V8 C/ recipients
of NKT cells on the response of transferred BDC2.5 T (data not shown). On day 6 after BDC2.5 T cell transfer,
cells. 80% of C/ and V14 C/ recipient mice and 100%
of V8 C/ recipient mice showed some degree of
islet infiltration. The levels of peri-insulitis and insulitisNKT Cells Prevent the Development of Diabetes
after Transfer of Naive BDC2.5 T Cells (corresponding to islet invasion and destruction) were
similar in C/ and V14 C/ recipients suggestingA first set of experiments was performed to evaluate the
capacity of NKT cells to inhibit the induction of diabetes that NKT cells do not inhibit BDC2.5 T cell migration
NKT Cells Inhibit T Cell Differentiation
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Figure 1. Characterization of the Three Types
of Recipient Mice
(A) Splenocytes and pancreatic lymph node
cells from 7-week-old mice were counted and
labeled with anti-. The values represent the
means obtained with three mice for each
group.
(B) Cells from pancreatic lymph nodes from
NK1.1 congenic mice were stained with anti-
 and anti-NK1.1 mAbs. The numbers repre-
sent the percentages in each quadrant (simi-
lar data were obtained with mesenteric lymph
nodes).
(C) Pancreatic and mesenteric lymph node
cells were pooled and either stimulated (black
bars) with anti-CD3 or -GalCer or cultured in
medium alone (white bars). Proliferation was
measured by [3H]thymidine incorporation.
The values represent the means of the results
obtained with three individual mice for each
group.
into pancreatic islets. However, on day 9—a few days we next examined the effect of NKT cells on the develop-
ment of the autoimmune response by BDC2.5 T cells.before diabetes onset in recipients devoid of NKT cells—
almost all pancreatic islets of both C/ and V8 C/ To follow the fate of anti-islet BDC2.5 T cells after their
transfer, CD62L CD4 cells from Thy1.1 BDC2.5 C/recipients were destroyed, whereas most V14 C/
recipients still contained islets free of infiltrating cells. NOD mice were injected into Thy1.2-recipient mice.
Since it has been previously reported that BCD2.5 T cellsInterestingly, analysis of protected V14 C/ mice up
to 50 days after transfer showed that there was no pro- were specifically activated in pancreatic lymph nodes
(Hoglund et al., 1999), we analyzed the homing ofgression in the severity of islet infiltration and that some
(2 out of 11) V14 C/ recipient mice were still totally BDC2.5 T cells into pancreatic lymph nodes (Figure 3A).
There were similar percentages of BDC2.5 T cells recov-devoid of islet infiltration. Immunostaining of pancreatic
sections revealed that intercellular adhesion molecule ered on day 2 in pancreatic lymph nodes of the three
types of recipients, C/, V8 C/, and V14 C/(ICAM)-1, a molecule expressed in inflamed tissue, was
strongly expressed in C/ recipients of BDC2.5 T cells mice. As the sizes of pancreatic lymph nodes of the
three recipients were similar (as shown in Figure 1A),but barely detectable in V14 C/ recipients (Figure
2E). These experiments demonstrate that NKT cells pre- the absolute numbers of homed BDC2.5 T cells were
not influenced by the presence of NKT cells. Signs ofvent diabetes development by inhibiting pancreatic islet
inflammation and  cell destruction by autoreactive T activation of BDC2.5 T cells were already detected in
pancreatic lymph nodes by day 2 after transfer. Sixty-cells.
one percent to seventy-seven percent of the BDC2.5 T
cells expressed the early activation marker, CD69 (Fig-NKT Cells Do Not Prevent the Acquisition
of an Activated Phenotype and the Initial ure 3A). By day 3, almost all detected CD62L CD44low
CD4 BDC2.5 cells had lost the CD62L marker andProliferation of Naive BDC2.5 T Cells
Because naive BDC2.5 T cells transferred to recipients upregulated the expression of CD44 and CD25 (Figure
3B and data not shown). Most importantly, BDC2.5containing NKT cells were unable to induce diabetes,
Immunity
728
Figure 2. NKT Cells Inhibit the Development of Diabetes and Reduce Insulitis Induced by CD62L and Unpurified BDC2.5 T Cells
CD4 T cells (0.25  106) from BCD2.5 C/ NOD mice were injected i.v. into various recipient mice.
(A) The panels represent the phenotypes of the three populations of CD4 BDC2.5 T cells injected (CD62L, unpurified, and differentiated
NKT Cells Inhibit T Cell Differentiation
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changes occurred to the same extent in all three types INF--producing cells and alter this cell’s ability to sus-
tain IL-2 production.of recipient mice (C/, V8 C/, and V14 C/).
Similarly, in all recipient mice, transferred BDC2.5 T cells
increased in size (as observed by FSC) suggesting NKT Cells Inhibit In Vitro Differentiation
equivalent blast transformation. To analyze the division of BDC2.5 T Cells into IFN--Producing Cells
of BDC2.5 T cells after their transfer, they were labeled The ability of NKT cells to interfere with BDC2.5 T cell
with the cytoplasmic dye CFSE, injected into the three differentiation in response to antigenic stimulation was
types of recipient mice and then analyzed on days 2 then tested in vitro. Naive BDC2.5 T cells stimulated with
and 3. On day 2, BDC2.5 T cells had not yet divided their specific peptide in the presence of APC strongly
(Figure 3A). By day 3, however, 85% of the recovered proliferated (dilution of CFSE) and produced IFN- and
BDC2.5 T cells from the C/-recipient mice had di- IL-2 (Figure 5). Similar to what was observed in vivo, the
vided. In the V8 C/ and V14 C/ recipients a presence of V14 T cells did not inhibit the proliferation
comparable percentage of the BDC2.5 T cells prolifer- of BDC2.5 T cells (Figure 5). More importantly, the pres-
ated, 81% and 80%, respectively (Figure 3B). These ence of V14 T cells but not the presence of V8 T cells
results show that NKT cells have no inhibitory effect on inhibited the production of IFN- and IL-2 by BDC2.5 T
the activation and early proliferation of BDC2.5 T cells. cells. These in vitro experiments directly confirmed that
NKT cells can inhibit BDC2.5 T cell differentiation into
IFN--producing cells.NKT Cells Inhibit the Differentiation of BDC2.5 T Cells
into IFN--Producing Cells and Alter BDC2.5
T Cell Ability to Sustain IL-2 Production Late Expansion and Proliferation of BDC2.5 T Cells
Are Inhibited in Recipients Containing NKT CellsTo analyze the effect of NKT cells on the differentiation
of BDC2.5 T cells, IFN- production was measured by We next analyzed the fate of BDC2.5 T cells that had
been primed in V14 C/ NOD recipients without dif-intracytoplasmic staining after stimulation with PMA
plus ionomycin (Figure 4A). As early as day 3 after trans- ferentiating well into effector cells and that were not
able to efficiently destroy  cells. The data obtainedfer, BDC2.5 T cells were producing IFN-. Thirty-one
percent and twenty-three percent of BDC2.5 T cells from with CFSE-labeled BDC2.5 T cells show that these cells
initially expanded to the same extent in the recipientscontrol C/ and V8 C/ recipients, respectively,
produced IFN-. In contrast, IFN- production was in- containing or not containing NKT cells (Figure 4B). Con-
sistent with this, we observed on days 3 and 4 that all theduced in only 8% of BDC2.5 T cells from V14 C/
recipient mice; also, the amount of IFN- per cell was recipients contained similar percentages and absolute
numbers of transferred BDC2.5 T cells in their pancreaticlower (as seen by the mean fluorescence intensity). In
contrast, the percentage of T cells producing TNF- lymph nodes (Figure 6A). However, by day 12 the per-
centages of BDC2.5 T cells in pancreatic lymph nodesalone was the same in all groups. Analysis of BDC2.5 T
cells on day 4 after transfer confirmed that their differen- were 4.5 times lower in V14 C/ recipient mice than
in C/ and V8 C/ control recipients (Figure 6A).tiation into IFN--producing cells in V14 C/ recipient
mice was impaired (Figure 4A). IL-2 production, usually The absolute numbers of BDC2.5 T cells on day 12 were
reduced 3- to 4-fold in V14 C/ mice compared toassociated with T cell proliferation, was analyzed by
intracytoplasmic staining of BDC2.5 T cells after their control recipients (Figure 6A). The percentage and abso-
lute number of BDC2.5 T cells in V14 C/ mice re-stimulation with PMA plus ionomycin. On day 3, 39%
of BDC2.5 T cells from C/ recipients produced IL-2 mained relatively stable from day 12 to day 20. C/
and V8 C/ mice were not tested at day 20 becausein comparison to half of BDC2.5 T cells from V8 C/
and V14 C/ recipients (Figure 4B). Analysis of IL-2 by this time they had all developed diabetes and been
sacrificed. Similar results were obtained with mesentericproduction on day 4, however, revealed that BDC2.5 T
cells from V14 C/ recipient mice were unable to lymph nodes (data not shown). To determine whether
the difference seen after day 6 in BDC2.5 T cell numberssustain a high level of IL-2 production. As shown in
Figure 4B, only 17% of BDC2.5 T cells from V14 C/ in the various recipient mice was due to a reduced rate
of proliferation, the mice were injected with bromode-recipients produced IL-2 versus 42% and 32% of
BDC2.5 T cells from C/ and V8 C/ recipients, oxyuridine (BrdU). On day 7 after transfer, a high per-
centage of BDC2.5 T cells in pancreatic lymph nodesrespectively. Overall, these results suggest that NKT
cells inhibit the differentiation of BDC2.5 T cells into incorporated BrdU in 1 hr (17% and 27% in C/ and
into Th1 cells). Cells were stained with anti-TCR, anti-CD4, anti-CD44 and anti-CD62L mAbs.
(B) The panels show the incidence of diabetes in C/ (), V8 C/ (), and V14 C/ () NOD mice after transfer of the three populations
of BDC2.5 T cells. The same incidence of diabetes was obtained when 0.25  106 or 106 CD62L BDC2.5 T cells were injected (data not
shown).
(C) CD62L CD4 BDC2.5 T cells were injected either into C/ recipients or into C/ mice reconstituted 3 weeks earlier with V14-J281
T cells as described in the Experimental Procedures.
(D) Pancreatic sections of C/, V8 C/, and V14 C/ NOD mice injected with CD62L CD4 BDC2.5 T cells (0.25  106) were analyzed
6, 9, or up to 50 days after transfer. Insulitis was scored as described in the Experimental Procedures. Each recipient mouse corresponds to
a bar.




V8 C/ mice, respectively; Figure 6B). Proliferation
was less vigorous in V14 C/ mice, as only 10% of
BDC2.5 T cells contained BrdU. By day 20 after transfer,
there was no BrdU incorporation by BDC2.5 T cells in
pancreatic lymph nodes of V14 C/ mice. The cessa-
tion of BDC2.5 T cell proliferation was also observed in
mesenteric lymph nodes (data not shown). Therefore,
the presence of NKT cells prevents the continued prolif-
eration of anti-islet T cells. In keeping with this observa-
tion, BDC2.5 T cells present on day 7 in pancreatic lymph
nodes of V14 C/ mice were smaller than BDC2.5 T
cells from control recipients (Figure 6C). By day 20, al-
most all BDC2.5 T cells from pancreatic lymph nodes
of V14 C/ mice were small. Interestingly, at this time
point, most BDC2.5 T cells, which were CD44high CD62L,
showed upregulated CD69 expression. This characteris-
tic has been described before for tolerized anergic T
cells (Lanoue et al., 1997; Tanchot et al., 1998, 2001).
BDC2.5 T Cells Primed in V14 C/
Recipients Become Anergic
As BDC2.5 T cells present in V14 C/ recipient mice
at later times appeared to have an altered capacity to
proliferate and as they had an unusual phenotype, we
analyzed their capacity to respond to stimulation in vitro.
BDC2.5 T cells were recovered on days 6 and 12 after
transfer, which was the latest time point when all three
types of recipients were still alive. BDC2.5 T cells were
also recovered from protected V14 C/ NOD mice
at day 28. As shown in Figure 7A, BDC2.5 T cells from
V14 C/-recipient mice were hyporesponsive to anti-
CD3 plus costimulation compared to BDC2.5 T cells
recovered from C/ and V8 C/ recipients. This
defective responsiveness, which involved IL-2 and IFN-
production as well as proliferation, was already ob-
served at day 6 and was more pronounced at days 12
and 28. The addition of exogenous IL-2 to day 12 cells
did not restore the proliferative response (Figure 7B). It
is also interesting to note that stimulation with PMA plus
ionomycin, which bypasses TCR signaling, was not able
Figure 3. NKT Cells Do Not Inhibit the Homing, the Acquisition of to overcome the deficiency in cytokine production, al-
Activated Phenotype, and the Initial Proliferation of Naive BDC2.5 though these chemicals did partially reconstitute the
T Cells
proliferative response. In particular, IL-2 production by
Thy-1.1 CD62L CD4 BDC2.5 T cells (106) were injected i.v. into BDC2.5 T cells from V14 C/ NOD mice remained
Thy-1.2 C/, V8 C/, and V14 C/ NOD mice.
10-fold lower than that of BDC2.5 T cells from control(A) Homing and activation of BDC2.5 T cells in pancreatic lymph
recipients (Figure 7B). Thus, BDC2.5 T cells that havenodes on day 2 after transfer. Pancreatic lymph node cells were
counted and stained with anti-TCR, anti-CD4, and anti-Thy1.1 been stimulated in the presence of NKT cells appear to
mAbs. Values correspond to the percentage of BDC2.5 T cells pres- become anergic.
ent in pancreatic lymph nodes of each recipient. In this experiment, To determine whether the presence of NKT cells had
BDC2.5 T cells had been previously labeled with CFSE. For CD69 favored differentiation of BDC2.5 T cells toward a non-expression, the cells were stained with anti-CD4, anti-Thy1.1, and
pathogenic Th2 cytokine profile, IL-4 and IL-10 produc-anti-CD69. Similar data (percentage of BDC2.5 T cells and CD69
tion was also analyzed by intracytoplasmic staining (Fig-expression) were obtained with four individual mice from each type
of recipient. ure 7C). The percentage of BDC2.5 T cells producing
(B) Phenotype, size, and cell division of BDC2.5 T cells from pancre- those cytokines was low (less than 10%) in all recipient
atic lymph nodes on day 3 after transfer. CD62L and CD44 expres- mice. The presence of NKT cells did not significantly
sion and FSC (bold line) was analyzed on BDC2.5 T cells (Thy-1.1
influence IL-4 or IL-10 production. Similar results wereCD4 cells). For comparison, FSC of the injected CD62L CD4
obtained with BDC2.5 T cells present in mesentericBDC2.5 T cells is shown (thin line). To analyze proliferation, cells
lymph nodes (data not shown). Thus, overall, the pres-were labeled with CFSE before their transfer. The values represent
the percentages of recovered BDC2.5 T cells ( TCR Thy-1.1 ence of NKT cells seemed mainly to inhibit the differenti-
CD4 cells) that had not divided. Similar results were obtained in ation of BDC2.5 T cells into IFN--producing cells and
three independent experiments performed with three mice in each to direct them into a deep anergic state not reversible
group.
by the addition of IL-2.
NKT Cells Inhibit T Cell Differentiation
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Figure 4. NKT Cells Inhibit the Differentiation
of BDC2.5 T Cells into IFN--Producing Cells
and Alter BDC2.5 T Cell Ability to Sustain IL-2
Production
Thy-1.1 CD62L CD4 BDC2.5 T cells (106)
were injected i.v. into Thy-1.2 C/, V8
C/, and V14 C/ NOD mice. On days
3 and 4, pancreatic lymph node cells from
the various recipients were stimulated in vitro
for 4 hr with PMA plus ionomycin before im-
munofluoresence staining was performed.
The percentages of cytokine-producing cells
among BDC2.5 T cells are indicated as well
as the mean fluorescence intensity (MFI) for
IFN- and IL-2 production.
(A) IFN- and TNF- production of BDC2.5 T
cells (Thy1.1  TCR cells).
(B) IL-2 production of BDC2.5 T cells (Thy-
1.1 CD4  TCR ). Similar results were
obtained in two independent experiments
performed with three mice in each group.
Discussion inhibit the activation of anti-islet T cells. The BDC2.5 T
cells acquired activation markers and proliferated after
encounter with their specific antigen in the pancreaticThis study reveals the precise effect of NKT cells on
conventional diabetogenic  CD4 T cells during acti- lymph nodes. However, the presence of NKT cells during
activation clearly impaired their differentiation into Th1vation of the latter in vivo. First, it shows that NKT cells
can protect against diabetes induced by naive (CD62L) effector cells. As early as day 3 after their transfer, the
percentage of BDC2.5 T cells producing IFN- and theBDC2.5 T cells but cannot prevent diabetes when
BDC2.5 cells are fully differentiated into Th1 cells prior amount of IFN- per cell were lower in V14 C/ recipi-
ents as compared to recipients not containing NKT cells.to their transfer. This result suggests that NKT cells
impair the differentiation of anti-islet T cells rather than Similar inhibition was also observed on days 4, 6, 12,
and 24 (data not shown). BDC2.5 T cells present in V14blocking the response of already activated T cells. It
also suggests that NKT cells are not very effective in C/ recipients were unable to induce significant islet
inflammation or to destroy the  cells. The inhibition ofkilling Th1 effector T cells. Previous studies have shown
that NKT cells can be cytotoxic through the Fas-FasL IFN- production might be the most critical effect in this
regard, because induction of diabetes in C/ mice byand perforin/granzyme pathways (Kaneko et al., 2000);
however, more recently it has been shown that apopto- injection of CD62L BDC2.5 T cells is totally prevented
by treatment with an anti-IFN--blocking mAb (data notsis of target cells observed after NKT cell activation
by -GalCer is due instead to subsequent activation of shown).
It is interesting to note that BDC2.5 T cells activatedconventional NK cells (Hayakawa et al., 2001). Second,
this transfer model revealed that NKT cells do not totally in vivo by their antigen in the presence of NKT cells
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Figure 5. NKT Cells Inhibit In Vitro the Differ-
entiation of Naive BDC2.5 T Cells into IFN--
Producing Cells
Thy-1.1 CD62L CD4 BDC2.5 T cells were
stimulated by the peptide 1040-51, in the
presence of APC and rIL-2. In some wells,
Thy-1.2 V8 T cells or V14 T cells were
added to the culture. Histograms and dot
plots correspond to CD4 Thy-1.1 cells.
Proliferation was measured at day 4 by the
dilution of CFSE. IFN- and IL-2 production
was determined by intracytoplasmic staining
at day 5.
resemble anergic T cells (Schwartz, 1996). As early as into Th2 cells. Previous studies, including those from
our laboratory, have shown that NKT cell-induced pro-day 4 after their transfer, only 2 days after the first signs
of cell activation, IL-2 production by BDC2.5 T cells from tection against diabetes can be associated with in-
creased Th2 responses (Hong et al., 2001; Lehuen et al.,V14 C/ recipients was already reduced, 17% versus
37% in control recipients. On day 12, the frequency of IL- 1998; Sharif et al., 2001). This was observed in untreated
V14 C/ transgenic NOD mice as well as in NOD2-producing BDC2.5 T cells from V14 C/ recipients
was even lower, 8% versus 40% in control recipients mice treated with -GalCer. These previous results were
obtained with polyclonal T cells, whereas the present(data not shown). More complete analysis performed on
days 6, 12, and 28 showed that BDC2.5 T cells from study was performed with a monoclonal T cell popula-
tion. It would be interesting to analyze the in vivo differ-V14 C/ recipients were refractory to various in vitro
stimulations, either with anti-CD3 mAb and costimula- entiation of other T cells (with various TCR affinities)
which normally express a Th2 phenotype in order totion (anti-CD28 mAb) or with PMA plus ionomycin. The
blockade in responsiveness was observed for prolifera- determine whether their differentiation is affected by the
presence of NKT cells. Indeed, our hypothesis wouldtion and IL-2 and IFN- production and was not over-
come by the addition of exogenous IL-2. This anergic be that high-affinity T cells, such as BDC2.5 T cells,
would be anergized when stimulated in the presence ofstate of the BDC2.5 T cells present in V14 C/ recipi-
ent mice is very similar to what has already been de- NKT cells while other T cells with lower affinities would
differentiate into Th2 cells. It is important to note thatscribed for T cells tolerized in vivo by the persistent
expression of known antigens (influenza hemagglutinin, in our previous studies with polyclonal T cells in NOD
mice, it was not possible to detect whether some high-HY, and pigeon cytochrome c) (Lanoue et al., 1997; Tan-
chot et al., 1998, 2001). It may represent the deepest affinity anti-islet T cells were anergized. The present
observation that high-affinity clones can be anergizedform of this state since it could not be overcome by
either IL-2 or PMA plus ionomycin. rather than pushed toward a Th2 phenotype is an impor-
tant finding as these T cells might be reactivated byThe NKT cell-mediated inhibition of naive T cell differ-
entiation into Th1 effector cells may explain several pre- various stimuli. Indeed, recent studies have shown that
activation through OX-40 or inhibition of CLTA-4 canvious observations. Diabetes-free NOD mice, in which
NKT cells are more frequent (V14 transgenic mice) or abrogate anergy and break peripheral T cell tolerance
(Bansal-Pakala et al., 2001; Greenwald et al., 2001;have been activated by injection with -GalCer, exhibit
subnormal Th1 responses within pancreatic islets and Luhder et al., 2000).
The absence of Th2 differentiation of BDC2.5 T cellsagainst islet autoantigens (Hong et al., 2001; Lehuen et
al., 1998; Sharif et al., 2001). Similarly, the presence of after their transfer into V14 C/ recipient mice does
not mean that Th2 cytokine production by NKT cellsNKT cells during tumor responses leads to a reduction
in the frequency of tumor-specific cytotoxic T cells (Ter- is not involved as part of their protection. However,
preliminary data suggest that neither IL-4 nor IL-10 isabe et al., 2000). It is interesting to note that the presence
of NKT cells did not induce BDC2.5 T cell differentiation necessary for the protection against diabetes induced
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Figure 6. NKT Cells Inhibit the Late Expan-
sion Of BDC2.5 T Cells
Thy-1.1 CD62L CD4 BDC2.5 T cells (106)
were injected i.v. into Thy-1.2 C/, V8
C/, and V14 C/ NOD mice.
(A) Percentages and absolute numbers of
Thy-1.1  TCR CD4 BDC2.5 T cells in the
lymphoid gate in the three types of recipient
mice. Results represent the mean values ob-
tained with five to six individual mice at each
time point. Data on day 20 is only shown for
V14 C/ NOD mice as the other recipients
got diabetes and were sacrificed.
(B) BrdU content of BDC2.5 T cells (Thy-1.1
 TCRCD4 cells). BrdU incorporation was
allowed to proceed for 1 hr in vivo. Values
represent the percentages of BDC2.5 T cells
that incorporated BrdU.
(C) FSC and CD69 expression on BDC2.5 T
cells. Data shown in (B) and (C) were obtained
on day 7 with BDC2.5 T cells from the three
types of recipient mice and on day 20 with
BDC2.5 T cells from diabetes-free V14 C/
NOD recipient mice. Similar results were ob-
tained in two independent experiments.
by BDC2.5 T cells. Further experiments are being per- and NOD mice with a decrease in NKT cell number may
be a reflection of this situation.formed to determine the role of other cytokines, such as
IL-13 and TGF-, that have previously been implicated in
the immunosuppression mediated by NKT cells (Ta- Experimental Procedures
mada et al., 1996; Terabe et al., 2000). It is important to
Micenote that this model of BDC2.5 cell transfer into V14
The V14-J281 transgenic NOD mouse and the NK1.1 congenicC/ mice precludes the involvement of other regula-
NOD mouse have already been described (Carnaud et al., 2001;
tory  T cells in the protection but does not rule out Laloux et al., 2001; Lehuen et al., 1998). V8 transgenic NOD mice
the involvement of other cell types. Preliminary studies were obtained by microinjection into NOD eggs of the V8-J37
gene segments from the IAd/rabbit Ig-specific T cell clone CDC35suggest that dendritic cells have a different phenotype
(Tony and Parker, 1985). Both lines were backcrossed to C/ NODwhen the immune response takes place in the presence
mice. BDC2.5 transgenic C/ NOD mice were obtained from Dr.of a large number of NKT cells, but it remains to be
Mathis and Benoist (Harvard Medical School, Boston). We gener-shown whether these modifications play a role in the
ated Thy1.1 BDC2.5 C/ NOD mice by breeding with NOD-
inhibition of CD4 T cell differentiation into Th1 cells. NON-Thy-1a mice (provided by Dr. Leiter, Jackson Laboratory, Bar
Even though the precise mechanism used by NKT Harbor, ME). In BDC2.5 C/ mice, all  T cells are CD4 V4.
All the mice used in this study were raised and housed in strictlycells remains to be determined, our study clearly demon-
controlled specific pathogen-free conditions.strates that NKT cells are able to inhibit the differentia-
tion of naive T cells into Th1 effectors. This inhibition was
Flow Cytometrystrong enough to block the development of diabetes.
For surface staining experiments, cells were stained at 4C in PBSHowever, the fact that NKT cells induced anergy in and
containing 1% BSA and 0.1% azide, after blocking Fc receptorsnot deletion of anti-islet T cells suggests that the pres-
by incubation with the anti-Fc-receptor mAb 2.4G2. Staining was
ence of NKT cells must be sustained in order to achieve performed with the following fluorochrome-conjugated or biotinyl-
long-term protection against the development of auto- ated mAbs: anti-NK1.1 (PK136), anti-TCR (H57), anti-Thy-1.1
(HO22.1), anti-CD3 (145-2C11), anti-CD4 (GK1.5), anti-CD44 (IM7),immune disease. The association of diabetes in humans
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Figure 7. NKT Cells Facilitate Anergy Induction in BDC2.5 T Cells
Equal numbers of Thy-1.1 CD62L CD4 BDC2.5 T cells (0.25 to 1  106) were transferred into Thy-1.2 C/, V8 C/, and V14 C/
NOD mice and analyzed on days 6, 12, and 28.
(A) In vitro response of cell-sorted BDC2.5 T cells. Thy-1.1 CD5 cells (104/well) were stimulated with immobilized anti-CD3 mAb in the
presence of soluble anti-CD28 mAb. After 48 hr, supernatants were harvested to measure IL-2 and IFN- release, and [3H]thymidine incorporation
was measured over the last 18 hr of a 64 hr culture period. The upper panels represent the results at day 6 after transfer of the three recipient
mice. The middle panels represent the results at day 12 after transfer of the three recipient mice. The lower panels represent data on day 12
for C/ NOD recipient and day 28 for V14 C/ NOD recipients as the other recipients got diabetes and were sacrificed. Similar results
were obtained in two independent experiments for day 6, 12, and 28.
(B) Addition of exogenous IL-2, as well as stimulation with PMA plus ionomycin did not reverse anergy of BDC2.5 T cells. Thy-1.1 CD5 cells
(104/well), recovered by cell sorting on day 12 after their transfer in both types of recipients, were stimulated with immobilized anti-CD3 mAb
or with PMA plus ionomycin in the presence of soluble anti-CD28 mAb and in the presence or absence of exogenous IL-2. After 48 hr,
supernatants were harvested to measure IL-2 and IFN- release, and [3H]thymidine incorporation was measured over the last 18 hr of a 64
hr culture period. Similar results were obtained in two independent experiments.
(C) IL-4 and IL-10 production by BDC2.5 T cells after PMA and ionomycin stimulation. Pancreatic lymph node cells were recovered from the
three types of recipient mice on day 12 after transfer of CD62L BDC2.5 T cells. Cells were stimulated for 4 hr with PMA plus ionomycin
before immunofluorescence staining. Similar results were obtained in two independent experiments and with mesenteric lymph nodes.
anti-CD62L (Mel14), and anti-CD69 (H1.2F3). Intracytoplasmic stain- control. These reagents (except anti-Thy-1.1 mAb) were purchased
from PharMingen (San Diego, CA). Stained cells were analyzed onings were performed as previously described (Laloux et al., 2002).
Cells from lymph nodes, as well as cells from in vitro culture, were a FACSCalibur flow cytometer (Becton Dickinson, Mountain View,
CA) using CellQuest software.stimulated 4 hr with PMA and ionomycin in the presence of Brefeldin
A. After surface staining, cells were fixed and permeabilized, and
then intracytoplasmic staining was performed using anti-mouse IL-2 In Vitro T Cell Stimulation
Pancreatic and mesenteric lymph node cells were pooled from eachmAb (JES6-5H4), anti-mouse IFN- mAb (XMG1.2) and anti-mouse
TNF- mAb (MP6), or anti-mouse IL-10 mAb (JES5) and anti-mouse mouse. Cells were incubated at 106/well in complete RPMI 1640
medium containing 10% FCS, in the presence of 5 g/ml of immobi-IL-4 mAb (11B11). PE-labeled rat IgG1 was used as the isotype
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lized anti-CD3 (2C11) or 100 ng/ml -GalCer. [3H]thymidine incorpo- the last 18 hr of a 64 hr culture period. ELISA methods were used
to detect the cytokines as previously described (Lehuen et al., 1998).ration was measured over the last 4 hr of a 48 hr culture period.
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